1. Orforglipron after Wegovy or Zepbound. ATTAIN-MAINTAIN found that patients transitioned from tirzepatide or semaglutide to oral orforglipron (Foundayo) maintained substantially more of their prior weight reduction than patients switched to placebo. A new option in the maintenance discussion. https://belite.com/orforglipron-maintenance-after-wegovy-zepbound/ 2. CagriSema vs. Zepbound. CagriSema delivered 23% average weight loss in its head-to-head trial —
